A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Phase of Trial: Phase I/II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PrECOG
- 10 Mar 2017 Planned number of patients changed from 49 to 52.
- 18 Apr 2016 Status changed from not yet recruiting to recruiting.
- 22 Mar 2016 New trial record